Korean J Women Health Nurs.  2013 Dec;19(4):201-210. 10.4069/kjwhn.2013.19.4.201.

Characteristics and Quality of Life in Gynecologic Cancer Patients with Chemotherapy-induced Peripheral Neuropathy

• Jeong JH
• Nho JH
• Kim GS
• Lee YE
• Yu SY
• Lee HJ
• Sim YM
• Lee YS

• KMID: 2307943
• DOI: http://doi.org/10.4069/kjwhn.2013.19.4.201

Abstract

PURPOSE
The purpose of this study was to identify chemotherapy induced peripheral neuropathy, quality of life of patients with gynecologic cancer.
METHODS
This was a cross-sectional survey design. We collected 130 patients with gynecologic cancer. They complete a self reported questionnaire including items related neuropathy and quality of life (FACT-GOG/Ntx subscale, FACT-G scale).
RESULTS
The neuropathy score was 14.3+/-7.9. The quality of life score was 64.8+/-16.4. The neuropathy induced significant difference according to diabetic status, difficulties in performing household chores and willing to discontinuity of chemotherapy. And duration of cancer diagnosis, neuropathy, number of total chemo agent associated with quality of life. There was a negative correlation between number of total chemo agent and quality of life. Neuropathy independently affected quality of life.
CONCLUSION
Chemotherapy induced peripheral neuropathy of patients with gynecologic cancer adversely affected women's quality of life and activities of daily living. To improve patient's quality of life, it is important that accurate assess and appropriately manage neuropathy in patients with gynecologic cancer.

Keyword

Gynecologic neoplasm; Chemotherapy induced peripheral neuropathy; Quality of life

MeSH Terms

Activities of Daily Living
Cross-Sectional Studies
Diagnosis
Drug Therapy
Family Characteristics
Female
Genital Neoplasms, Female
Humans
Peripheral Nervous System Diseases*
Quality of Life*
Surveys and Questionnaires
Self Report

Reference

1. Bakitas MA. Background noise: The experience of chemotherapy-induced peripheral neuropathy. Nurs Res. 2007; 56:323–331. http://dx.doi.org/10.1097/01.nnr.0000289503.22414.79.

2. Bartlett JE, Kotrlik JW, Higgins CC. Organizational research: Determining appropriate sample size in survey research. Inf Technol Learn Perform J. 2001; 19:43–50.

3. Berek JS. Berek & Novak's Gynecology. 14ed. Philadelphia: Lippincott;2007.

4. Calhoun EA, Welshman EE, Chang CH, Lurain JR, Fishman DA, Hunt TL, et al. Psychometric evaluation of functional assessment of cancer therapy/gynecologic oncology group-neurotoxicity(FACT/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer. 2003; 13:741–748.

5. Cella D. Manual of the functional assessment of chronic illness therapy (FACIT) measurement system. Evanston: IL:Center on outcomes research and education (CORE);Evanston Northwestern Healthcare and Northwestern University;1997.

6. Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy induced peripheral neuropathy. Semin Oncol. 2006; 33:15–49.

7. Kaley TJ, Deangelis LM. Therapy of chemotherapy-induced peripheral neuropathy. Br J Haematol. 2009; 145:3–14. http://dx.doi.org/10.1111/j.1365-2141.2008.07558.x.

8. Kim HM. Symptoms and relief therapy related to chemotherapy induced peripheral neuropathy in patients with cancer. Daegu: Keimyoung University;2012. Unpublished master's thesis.

9. Kim JH, Choi KS, Kim TW, Hong YS. Quality of life in colorectal cancer patients with chemotherapy-induced peripheral neuropathy. J Korean Oncol Nurs. 2011; 11:254–262. http://dx.doi.org/10.5388/jkon.2011.11.3.254.

10. Kiser DW, Greer TB, Wilmoth MC, Dmochowski J, Naumann RW. Peripheral neuropathy in patients with gynecologic cancer receiving chemotherapy: Patient reports and provider assessments. Oncol Nurs Forum. 2010; 37:758–764. http://dx.doi.org/10.1188/10.ONF.758-764.

11. Kwak MK, Kim EJ, Lee ER, Kwon IG, Hwang MS. Characteristics and quality of life in patients with chemotherapy-induced peripheral neuropathy. J Korean Oncol Nurs. 2010; 10:231–239.

12. Long HJ, Monk BJ, Huang HQ, Grendys EC, McMeekin DS, Sorosky J, et al. Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A gynecologic oncology group study. Gynecol Oncol. 2006; 100:537–543.

13. Mantyh PW. Cancer pain and its impact on diagnosis, survival and quality of life. Nat Rev Neurosci. 2006; 7:797–809.

14. Pan Y, Kao MS. Discordance of clinical symptoms and electrophysiologic findings in taxane plus platinum-induced neuropathy. Int J Gynecol Cancer. 2007; 17:394–397. http://dx.doi.org/10.1111/j.1525-1438.2006.00766.x.

15. Park AR, Kim SJ, Bang JS, La HO. Oxaliplatin-induced peripheral neuropathy in patients with advanced or metastatic gastric cancer. Korean J Clin Pharm. 2009; 19:18–22.

16. Rao RD, Michalak JC, Sloan JA, Loprinzi CL, Soori GS, Nikcevich DA, et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: A phase 3 randomized, double-blind, placebo-controlled, cross-over trial. Cancer. 2007; 110:2110–2118. http://dx.doi.org/10.1002/cncr.23008.

17. Smith EL, Whedon MB, Bookbinder M. Quality improvement of painful peripheral neuropathy. Semin Oncol Nurs. 2002; 18:36–43.

18. Smith EM, Beck SL, Cohen J. The total neuropathy score: A tool for measuring chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum. 2008; 35:96–102. http://dx.doi.org/10.1188/08.ONF.96-102 .

19. Cancer occurrence ratio in Korea women. Statistics Korea;2010. Retrieved July, 15, 2013. from http://kosis.kr/wnsearch/totalSearch.jsp.

20. Sweeney CW. Understanding peripheral neuropathy in patients with cancer: Background and patients assessment. Clin J Oncol Nurs. 2002; 6:163–166.

21. Tofthagen C. Patient perceptions associated with chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs. 2010; 14:E22–E28. http://dx.doi.org/10.1188/10.CJON.E22-E28.

22. Tofthagen C, McAllister RD, McMillan SC. Peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin. Clin J Oncol Nurs. 2011; 15:182–188. http://dx.doi.org/10.1188/11.CJON.182-188.

23. Verstappen CC, Heimans JJ, Hoekman K, Postma TJ. Neurotoxic complication of chemotherapy in patients with cancer: Clinical signs and optimal management. Drugs. 2003; 63:1549–1563.

24. Viens P, Petit T, Yovine A, Bougnoux P, Deplanque G, Cottu PH, et al. A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advancedovarian cancer patients. Ann Oncol. 2006; 17:429–436. http://dx.doi.org/10.1093/annonc/mdj097.

25. Wickham R. Chemotherapy-induced peripheral neuropathy: A review and implications for oncology nursing practice. Clin J Oncol Nurs. 2007; 11:361–376.

26. Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapy-induced peripheral neuropathy: Prevention and treatment strategies. Eur J Cancer. 2008; 44:1507–1515. http://dx.doi.org/10.1016/j.ejca.2008.04.018.

27. Yarbro CH, Frogge MH, Goodman M. Cancer symptom management. 3rd ed. Boston: Jones and Bartlett;2004.